ClearNote Health Boosts Pancreatic Cancer Test Sensitivity Ahead of AACR Showcase
Event summary
- ClearNote Health's Avantect® Pancreatic Cancer Test now achieves 82.6% sensitivity and 97.5% specificity in high-risk patients.
- The test will be featured at the AACR Annual Meeting 2026 (April 17-22) with new data presentations on early detection and treatment response.
- ClearNote Health's Virtuoso™ epigenomics platform is being integrated into major studies like NHS UK’s SAFE-D and NCI’s Vanguard Study.
The big picture
ClearNote Health is positioning itself as a leader in early cancer detection, leveraging its proprietary 5hmC technology to address one of oncology’s most challenging diagnoses. The company’s integration into large-scale studies like the NHS UK’s SAFE-D and NCI’s Vanguard Study signals growing validation of its approach. If successful, this could set a new standard for pancreatic cancer screening in high-risk populations.
What we're watching
- Clinical Validation
- Whether the enhanced Avantect test can maintain performance metrics in larger, real-world validation studies.
- Market Adoption
- The pace at which NHS UK’s SAFE-D and PRECEDE Consortium integrate the test into standard care protocols.
- Competitive Positioning
- How ClearNote Health differentiates itself against other liquid biopsy players in pancreatic cancer detection.
Related topics